Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by OSE Immunotherapeutics

OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO
From OSE Immunotherapeutics
Via GlobeNewswire
OSE Immunotherapeutics Presents Positive Preclinical Data on Combination of Anti-IL-7 Receptor Lusvertikimab in Chronic Colitis In Oral Presentation at 20th Congress of ECCO
From OSE Immunotherapeutics
Via GlobeNewswire
OSE Immunotherapeutics and Scienta Lab Establish Strategic Partnership to Leverage Artificial Intelligence in Precision Immunotherapy
From OSE Immunotherapeutics
Via GlobeNewswire
OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer
From OSE Immunotherapeutics
Via GlobeNewswire
OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary Cancer Vaccine Tedopi®
From OSE Immunotherapeutics
Via GlobeNewswire
OSE Immunotherapeutics Strengthens Leadership and Executive Committee
From OSE Immunotherapeutics
Via GlobeNewswire
OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis
From OSE Immunotherapeutics
Via GlobeNewswire
OSE Immunotherapeutics Presents New “Cis-Demasking” Bispecific Technology for the Design of Cytokine Drugs with Improved Therapeutic Index
From OSE Immunotherapeutics
Via GlobeNewswire
OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update
From OSE Immunotherapeutics
Via GlobeNewswire
OSE Immunotherapeutics Announces Global Launch of Artemia Phase 3 Registration Study for Cancer Vaccine Tedopi® in Second-Line Non-Small Cell Lung Cancer
From OSE Immunotherapeutics
Via GlobeNewswire
OSE Immunotherapeutics Announces Positive Efficacy Results for Lusvertikimab in the Phase 2 trial for the treatment of Ulcerative Colitis
From OSE Immunotherapeutics
Via GlobeNewswire
Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371
From OSE Immunotherapeutics
Via GlobeNewswire
OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’
From OSE Immunotherapeutics
Via GlobeNewswire
OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies
From OSE Immunotherapeutics
Via GlobeNewswire
OSE Immunotherapeutics Presents Preclinical Data on mRNA Therapeutic Platform for the Treatment of Inflammatory and Autoimmune Disorders at the FOCIS Annual Meeting, San Francisco (June 18 – 21)
From OSE Immunotherapeutics
Via GlobeNewswire
OSE Immunotherapeutics Reports on its 2024 General Shareholders’ Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic Company’s Growth
From OSE Immunotherapeutics
Via GlobeNewswire
OSE Immunotherapeutics KOL Investor Webinar on the Therapeutic Landscape and Unmet Medical Needs in Non-Small Cell Lung Cancer by Dr Stephen Liu and Prof Benjamin Besse
From OSE Immunotherapeutics
Via GlobeNewswire
OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant
From OSE Immunotherapeutics
Via GlobeNewswire
OSE Immunotherapeutics Provides Business and Corporate Update
From OSE Immunotherapeutics
Via GlobeNewswire
OSE Immunotherapeutics and Boehringer Ingelheim expand collaboration to develop first-in-class treatments for cancer and cardio-renal-metabolic diseases
From OSE Immunotherapeutics
Via GlobeNewswire
OSE Immunotherapeutics’ Global License to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation Becomes Effective
From OSE Immunotherapeutics
Via GlobeNewswire
OSE Immunotherapeutics Announces Peer-Reviewed Publication on Novel Myeloid Immune Checkpoint CLEC-1 in Journal of Immunology
From OSE Immunotherapeutics
Via GlobeNewswire
OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update
From OSE Immunotherapeutics
Via Business Wire
OSE Immunotherapeutics Highlights Clinical Portfolio Advancements and Provides 2024 Outlook
From OSE Immunotherapeutics
Via Business Wire
OSE Immunotherapeutics Announces First Clinical Results for BI 770371, a Novel Anti-SIRPα Monoclonal Antibody
From OSE Immunotherapeutics
Via Business Wire
OSE Immunotherapeutics Announces: Positive Phase 3 Data from its Cancer Vaccine in Lung Cancer Patients with Resistance to Previous Immunotherapy Published in Annals of Oncology
From OSE Immunotherapeutics
Via Business Wire
OSE Immunotherapeutics Announces for Lusvertikimab, its Anti-IL-7 Receptor Antagonist:
From OSE Immunotherapeutics
Via Business Wire
OSE Immunotherapeutics Announces New US Patent Granted for the Use of Tedopi® in Cancer Patients after Failure with PD-1/PD-L1 Immune Checkpoint Inhibitor Treatment
From OSE Immunotherapeutics
Via Business Wire
OSE Immunotherapeutics Receives €1.5 M in Funding from Bpifrance for the Development of a Companion Diagnostic for the Cancer Vaccine Tedopi® in Non-Small Cell Lung Cancer
From OSE Immunotherapeutics
Via Business Wire
OSE Immunotherapeutics Presents Additional Preclinical Updates on CLEC-1, a Novel Myeloid Immune Checkpoint in Immuno-Oncology
From OSE Immunotherapeutics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.